株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

サルコペニア : パイプライン分析

Sarcopenia - Pipeline Review, H1 2019

発行 Global Markets Direct 商品コード 213093
出版日 ページ情報 英文 71 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.86円で換算しております。
Back to Top
サルコペニア : パイプライン分析 Sarcopenia - Pipeline Review, H1 2019
出版日: 2019年02月01日 ページ情報: 英文 71 Pages
概要

サルコペニアとは、加齢に伴う筋力の量・機能の低下と定義されています。主な症状として、肥満や歩行・移動障害、筋力不足、呼吸困難などが挙げられます。主な治療法には、薬物療法やホルモン置換療法などがあります。

当レポートでは、世界各国でのサルコペニア治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

サルコペニアの概要

治療薬の開発

  • サルコペニア向けパイプライン製品:概要
  • サルコペニア向けパイプライン製品:比較分析

各企業で開発中のサルコペニア治療薬

大学/研究機関で研究中のサルコペニア治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品

サルコペニア治療薬:開発中の製品の一覧(企業別)

サルコペニア治療薬:研究中の製品の一覧(大学/研究機関別)

サルコペニア治療薬の開発に従事している企業

  • GlaxoSmithKline Plc
  • Myos Corporation
  • Neurotune AG
  • Novartis AG
  • PolyNovo Limited
  • PsiOxus Therapeutics Limited
  • Regeneron Pharmaceuticals, Inc.
  • 大日本住友製薬

サルコペニア:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • AOD-9604
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • ARM-210
  • bimagrumab
  • BIO-101
  • BIO-103
  • Espindolol
  • NEP-28
  • NT-1654
  • 筋骨格障害向けタンパク質
  • サルコペニア向け遺伝子組み換え型タンパク質
  • S-107
  • サルコペニア・悪液質向け Furin 阻害剤
  • 慢性関節リウマチ・サルコペニア・悪液質向け JAK3 阻害剤
  • trevogrumab

サルコペニア治療薬:パイプライン製品の最新動向

サルコペニア治療薬:開発が休止状態の製品

サルコペニア治療薬:開発が中止された製品

サルコペニア関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

図表

List of Tables

  • Number of Products under Development for Sarcopenia, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Sarcopenia - Pipeline by Armgo Pharma Inc, H1 2019
  • Sarcopenia - Pipeline by Biophytis SA, H1 2019
  • Sarcopenia - Pipeline by Faraday Pharmaceuticals Inc, H1 2019
  • Sarcopenia - Pipeline by Immusoft Corp, H1 2019
  • Sarcopenia - Pipeline by MYOS RENS Technology Inc, H1 2019
  • Sarcopenia - Pipeline by Neurotune AG, H1 2019
  • Sarcopenia - Pipeline by Novartis AG, H1 2019
  • Sarcopenia - Pipeline by Regeneron Pharmaceuticals Inc, H1 2019
  • Sarcopenia - Pipeline by ST Pharm Co Ltd, H1 2019
  • Sarcopenia - Pipeline by Teijin Pharma Ltd, H1 2019
  • Sarcopenia - Dormant Projects, H1 2019

List of Figures

  • Number of Products under Development for Sarcopenia, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019
目次
Product Code: GMDHC11084IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sarcopenia - Pipeline Review, H1 2019, provides an overview of the Sarcopenia (Musculoskeletal Disorders) pipeline landscape.

Sarcopenia is an aging-associated condition which is characterized by loss of muscle mass, strength and function. Symptoms include weakness, loss of endurance and poor balance. Causes of sarcopenia include a reduction in the nerve cells, low hormone levels and decline in body's ability to convert protein to energy. Treatment includes hormone replacement therapy (HRT), exercise and dietary supplements.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sarcopenia - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Sarcopenia (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sarcopenia (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sarcopenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 1, 7, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Sarcopenia (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Sarcopenia (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Sarcopenia (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Sarcopenia (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Sarcopenia (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Sarcopenia (Musculoskeletal Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Sarcopenia (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Sarcopenia (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Sarcopenia - Overview
  • Sarcopenia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Sarcopenia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Sarcopenia - Companies Involved in Therapeutics Development
    • Armgo Pharma Inc
    • Biophytis SA
    • Faraday Pharmaceuticals Inc
    • Immusoft Corp
    • MYOS RENS Technology Inc
    • Neurotune AG
    • Novartis AG
    • Regeneron Pharmaceuticals Inc
    • ST Pharm Co Ltd
    • Teijin Pharma Ltd
  • Sarcopenia - Drug Profiles
    • ARM-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVGN-7 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bimagrumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIO-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic for Muscle Wasting Disorders and Sarcopenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Inhibit SARM1 for Sarcopenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Sarcopenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KT-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KT-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KT-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NT-1654 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Protein for Sarcopenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Sarcopenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit NNMT for Sarcopenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Cyclooxygenase 2 for Sarcopenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit JAK3 for Cachexia, Rheumatoid Arthritis and Sarcopenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sodium iodide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TEISARM-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trevogrumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Sarcopenia - Dormant Projects
  • Sarcopenia - Product Development Milestones
    • Featured News & Press Releases
      • Dec 07, 2018: BIOPHYTIS announces one oral presentation and two poster presentations at the 11th international conference on cachexia, sarcopenia and muscle wasting
      • Nov 27, 2018: BIOPHYTIS to host Key Opinion Leader Meeting on the biology of Aging and its application in Neuromuscular Diseases
      • Sep 04, 2018: Biophytis provides enrollment update in its phase 2b SARA-OBS and SARA-INT studies of Sarconeos in sarcopenia
      • May 24, 2018: BIOPHYTIS: Inclusion of the First Patient in Phase 2b Study in Sarcopenia
      • Mar 01, 2018: BIOPHYTIS updates on SARA clinical study of Sarconeos in sarcopenia and presents four posters at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Miami
      • Dec 08, 2017: Biophytis Presents 4 Posters on Sarconeos at 10th International Conference on Cachexia, Sarcopenia, and Wasting Disorders (SCWD)
      • Dec 04, 2017: Biophytis has FAMHP Approval to conduct SARA-INT phase 2b Interventional Study of Sarconeos in Sarcopenia in Belgium
      • Oct 30, 2017: BIOPHYTIS Has FDA Approval to Initiate SARA-INT Phase 2b Interventional Study of Sarconeos in Sarcopenia
      • Sep 25, 2017: Biophytis filed IND application for approval by FDA of SARA-INT Phase 2b study of Sarconeos in Sarcopenia
      • May 11, 2017: BIOPHYTIS: First patient-in in the United States and opening of 2 clinical centers for the SARA-OBS study on Sarcopenia
      • May 03, 2017: BIOPHYTIS confirms that Sarconeos modulates the Renin-Angiotensin System and activates muscular metabolism in the SARA-PK clinical trial
      • Mar 27, 2017: Biophytis opens the first clinical centers in Europe and starts the recruitment of sarcopenic patients for SARA-OBS study
      • Mar 21, 2017: BIOPHYTIS to present on BIO101 at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Barcelona
      • Mar 01, 2017: BIOPHYTIS: Full results of SARA-PK study confirm Sarconeos good pharmacokinetic profile in elderly patients
      • Dec 16, 2016: Biophytis presents preliminary clinical data of SARA - PK, and new preclinical data of Sarconeos for treating sarcopenia
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top